# MOMENTUM (NCT04173494)

> A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

No report yet. It can be ordered.

- Drugs tested: momelotinib
- Indication: symptomatic, anemic JAK inhibitor-experienced myelofibrosis

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04173494
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Sierra Oncology LLC - a GSK company
- Conditions: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
- Interventions: Momelotinib; Placebo to match danazol; Danazol; Placebo to match momelotinib
- Enrollment: 195
- Primary outcome: Total Symptom Score (TSS) Response Rate at Week 24

## Indexed commentary on MOMENTUM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=momentum-nct04173494